Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences
19 April 2022 - 10:00PM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing targeted protein degradation to
deliver novel small molecule protein degrader medicines, today
announced that the Company will report first quarter 2022 financial
results on May 3rd, 2022 and will host a conference call at 8AM ET.
The Company will also participate in several upcoming investor
conferences and events.
“As Kymera approaches the two-year anniversary of
our initial public offering and is now a clinical stage company
across three unique programs, we will be providing a broad update
on our programs and pipelines on our first quarterly results
conference call,” said Nello Mainolfi, PhD, Co-Founder, President
and CEO, Kymera Therapeutics. “We are looking forward to engaging
with all our stakeholders through these quarterly calls on the
progress we are making toward building Kymera into a best-in-class,
fully-integrated degrader medicines company.”
To access the conference call via phone, please
dial 833-740-0921 (U.S.) or +1 409-937-8885 (International) and use
the conference ID 2984916. A live webcast of the event will be
available under “Events and Presentations” in the Investors section
of the Company’s website at www.kymeratx.com. A replay of the
webcast will be archived and available for one month following the
event.
Kymera Therapeutics also announced that the Company
will participate in the following upcoming investor
conferences:
- Piper Sandler Boston Biotech Bus Tour:Fireside Chat with Kymera
Management Team on May 5th at 11:15 AM ET
- Bank of America Healthcare Conference:Fireside Chat with Nello
Mainolfi, PhD on May 12th at 11:00 AM ET
- JP Morgan CEO Call Series:Call with Nello Mainolfi, PhD on May
17th at 1:00 PM ET
- UBS Global Healthcare Conference:Fireside Chat with Nello
Mainolfi, PhD on May 23rd at 1:15 PM ET
- HC Wainwright Annual Global Life Sciences Conference:Virtual on
demand presentation by Nello Mainolfi, PhD on May 24th, available
starting from 7:00 AM ET
Presentation webcasts will be available under
"Events and Presentations" in the Investors section of the
Company's website at www.kymeratx.com. Archived webcast replays
will be available on the website for approximately 90 days.
About Kymera TherapeuticsKymera
Therapeutics (Nasdaq: KYMR) is a biopharmaceutical company
pioneering the field of targeted protein degradation, a
transformative approach to address disease targets and pathways
inaccessible with conventional therapeutics. Kymera’s Pegasus
platform is a powerful drug discovery engine, advancing novel small
molecule therapies that harness the body’s innate protein recycling
machinery to degrade dysregulated, disease-causing proteins. With a
focus on undrugged nodes in validated pathways, Kymera is advancing
a pipeline of novel therapeutics designed to address the most
intractable pathways and provide new treatments for patients.
Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within
the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to
treat patients with a broad range of immune-inflammatory diseases,
hematologic malignancies, and solid tumors. For more information,
visit www.kymeratx.com.
Founded in 2016, Kymera is headquartered in
Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology
company by Fierce Biotech and has been recognized by the Boston
Business Journal as one of Boston’s “Best Places to Work.” For more
information about our people, science, and pipeline, please visit
www.kymeratx.com or follow us on Twitter or LinkedIn.
Investor Contact:Bruce Jacobs
Chief Financial Officer investors@kymeratx.com857-285-5300
Chris BrinzeyManaging Director,
Westwickechris.brinzey@westwicke.com339-970-2843
Media Contact:Tyler
GagnonDirector, Corporate
Communicationstgagnon@kymeratx.com508-904-9446
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Jul 2023 to Jul 2024